GNPX
Genprex, Inc.
$0.49
+0.03 (+6.05%)
At close · Jul 15
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of its recurring losses from operations and the need for additional financing to fund its operating and capital requirements, there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern.”View the 10-Q filed May 13, 2026
Market Cap
$84.69M
Shares
10,586,402
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2024
Net Income
-$16.23M
+23.1%
FY2025
Operating Cash Flow
-$15.31M
+14.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | $0 | $0 | $0 | $0 | $0 | — | $0 | $0 | $0 | |
| $9.63M | $9.43M | $10.54M | $17.62M | $11.51M | $8.97M | $7.3M | $1.97M | $971.43K | $289.93K | $354.88K | |
| $6.41M | $6.09M | $10.63M | $13.43M | $12.3M | $11.68M | $10.64M | $8.7M | $11.39M | $3.02M | $3.78M | |
| — | — | $773.48K | $0 | — | — | — | — | — | — | — | |
| $16.04M | $15.52M | $21.17M | $31.06M | $23.83M | $20.67M | $17.96M | $10.68M | $12.36M | $3.31M | $4.13M | |
| -$16.04M | -$15.52M | -$21.17M | -$31.06M | -$23.83M | -$20.67M | -$17.96M | -$10.68M | -$12.36M | -$3.31M | -$4.13M | |
| $30.58K | — | — | — | — | — | — | — | $37.98K | $1890 | $0 | |
| $18.78K | — | $63.57K | $215.11K | $90.1K | $5133 | $18.81K | $27.91K | $29.18K | $80 | $0 | |
| — | — | — | — | — | — | — | — | -$8798 | -$1810 | $0 | |
| — | $0 | $2650 | $0 | $0 | — | — | — | — | — | — | |
| -$16.73M | -$16.23M | -$21.11M | -$30.86M | -$23.74M | -$20.66M | -$17.94M | -$10.65M | -$12.37M | -$3.31M | -$4.13M | |
| — | -$16.23M | -$21.39M | -$30.86M | — | — | — | — | — | — | — | |
| USD/shares | — | -$17.40 | -$266.89 | -$1,128.00 | -$990.00 | -$880.00 | — | — | — | — | — |
| shares | — | 932.73K | 80.14K | 27.35K | 23.98K | 23.55K | 17.76K | 8013.49 | 6885.51 | 5750.016 | 5417.3425 |
| shares | — | — | — | — | — | 23.55K | 17.76K | 8013.49 | 6885.51 | 5750.016 | 5417.3425 |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.53×
EV/EBIT
—
Biotechnology median 26.49×
P/E (TTM)
—
Biotechnology median 7.39×